title: OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.
abstract: OBJECTIVE
  Bone turnover is regulated locally by osteoprotegerin (OPG) and receptor activator of NFkappaB ligand (RANK-L); it is not known how the circulating concentrations of these cytokines reflect renal osteodystrophy.
  
  
  METHODS
  We measured serum OPG, RANK-L, parathyroid hormone (iPTH), collagen C-terminal cross-linked telopeptide (betaCrossLaps), and bone densitometry (BMD) in 79 patients with end-stage renal disease (ESRF) undergoing dialysis. A hand X-ray of these patients was also analyzed. Controls were 65 healthy subjects.
  
  
  RESULTS
  ESRF patients had high OPG and RANK-L levels; RANK-L was higher in hemodialysis than in peritoneal dialysis. OPG and RANK-L did not depend on iPTH. The bone markers were significantly increased and correlated with serum iPTH, but not with OPG or RANK-L; neither OPG nor RANK-L correlated significantly with BMD. OPG was significantly higher in patients with acro-osteolysis.
  
  
  CONCLUSIONS
  OPG and RANK-L serum concentrations do not strongly reflect bone status in ESRF. However, OPG was significantly higher in patients with acro-osteolysis.
authors.affiliation: Laboratory of Haematology, CHU Brugmann, Place Van Gehuchten, 4, 1020 Brussels, Belgium.
authors.forename: Eric
authors.initials: E
authors.lastname: Wittersheim
authors.forename: Maria
authors.initials: M
authors.lastname: Mesquita
authors.forename: Anne
authors.initials: A
authors.lastname: Demulder
authors.forename: Martine
authors.initials: M
authors.lastname: Guns
authors.forename: Olivia
authors.initials: O
authors.lastname: Louis
authors.forename: Christian
authors.initials: C
authors.lastname: Melot
authors.forename: Max
authors.initials: M
authors.lastname: Dratwa
authors.forename: Pierre
authors.initials: P
authors.lastname: Bergmann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D005260:Female; D006023:Glycoproteins / Q000378:metabolism*; D006225:Hand / Q000000981:diagnostic imaging; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D053244:Osteoprotegerin; D010530:Peritoneal Dialysis; D053245:RANK Ligand; D011859:Radiography; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism*; D006435:Renal Dialysis
chemical_list: D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human